MBRX · Moleculin Biotech, Inc.

Substantial doubt about the company's ability to continue as a going concern.

“As of June 30, 2026, the Company had an accumulated deficit of $226.5 million since inception and had not yet generated any revenues from operations. Additionally, management anticipates that its cash on hand of $7.3 million as of June 30, 2026, is not sufficient to fund its planned operations for a period of at least one year from when these condensed consolidated financial statements are issued. These factors raise substantial doubt regarding the Company's ability to continue as a going concern.”